{"id":509603,"date":"2021-07-06T07:33:14","date_gmt":"2021-07-06T11:33:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-announces-positive-interim-results-from-phase-1b-study-of-aro-hif2-for-treatment-of-clear-cell-renal-cell-carcinoma\/"},"modified":"2021-07-06T07:33:14","modified_gmt":"2021-07-06T11:33:14","slug":"arrowhead-announces-positive-interim-results-from-phase-1b-study-of-aro-hif2-for-treatment-of-clear-cell-renal-cell-carcinoma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arrowhead-announces-positive-interim-results-from-phase-1b-study-of-aro-hif2-for-treatment-of-clear-cell-renal-cell-carcinoma\/","title":{"rendered":"Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma"},"content":{"rendered":"

<\/p>\n

Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma<\/b><\/p>\n

PASADENA, Calif.–(BUSINESS WIRE<\/a>)–
\nArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim results from the first two cohorts of AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company\u2019s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC). ARO-HIF2 is the first tumor-targeted investigational medicine to utilize Arrowhead\u2019s proprietary Targeted RNAi Molecule (TRiM\u2122) platform in a clinical trial. Arrowhead is currently enrolling the third planned patient cohort of AROHIF21001 and the company intends to present additional data at an appropriate medical congress.\n<\/p>\n

\nJames Hamilton, M.D., MBA, senior vice president of discovery and translational medicine at Arrowhead, said: \u201cThe AROHIF21001 Phase 1b study is designed to evaluate safety as well as preliminary pharmacodynamics and efficacy in an advanced ccRCC patient population. We believe that in the first two dose cohorts investigational ARO-HIF2 is showing clear signs of meaningful target engagement and some potentially early signs of efficacy in at least one patient. This is an encouraging start for the study. Specifically, in seventeen patients treated with investigational ARO-HIF2, nine had tumor biopsy material that could be evaluated. Seven of these nine tumor samples demonstrated reductions in HIF2\u03b1 protein, as measured by immunohistochemistry H-score. The mean of these reductions was -48% with a range from -9% to -82%. In addition, one patient achieved a partial response with tumor shrinkage of approximately 65% and four additional patients in cohort 2 remain on study drug with stable disease. Tumors typically have a high level of heterogeneity and the patients in AROHIF21001 have advanced ccRCC and have failed multiple lines of treatment including checkpoint inhibitors and anti-VEGF regimens, so these early results in a heavily pre-treated population are encouraging for investigational ARO-HIF2 and our tumor-targeted platform broadly. ARO-HIF2 has been generally well-tolerated and we look forward to continued dose escalation.\u201d\n<\/p>\n

Key Results from AROHIF21001<\/b><\/p>\n